Trial Profile
A PHASE 3, PLACEBO CONTROLLED, DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE (iNO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): INOvation-1 (Part 1 and Part 2)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms INOvation-1
- Sponsors Bellerophon Therapeutics
- 28 Feb 2019 This trial has been discontinued in Netherlands, according to European Clinical Trials Database.
- 09 Oct 2018 Interim results presented in a Bellerophon Therapeutics media release.
- 07 Aug 2018 According to a Bellerophon Therapeutics media release, the company is planning to analyse the full data set available from interim analysis in order to determine the next steps in our PAH program.